Intellia Therapeutics Inc. logo

Intellia Therapeutics Inc.

NTLA | NASDAQ
Chart Builder DCF Calculator
$12.22
+$0.08 (+0.66%)
At close: Sep 21, 2026, 4:00 PM ET
$12.22
$0 (0.00%)
Pre-market: Sep 22, 2026, 5:02 AM ET

Market Data

Market Cap
$1.7B
Enterprise Value
$1.34B
Beta
1.82
Average Volume
5.34M
Shares Outstanding (Diluted)
133.48M
Shares Change YoY
28.68%
Institutional Ownership
93.21%
Exchange
NASDAQ
ISIN
US45826J1051

Price Performance

Price Change 1M
-3.0%
Price Change 3M
-19.9%
Price Change 6M
-7.8%
Price Change YTD
32.7%
Price Change 1Y
-29.2%
Price Change 3Y
-62.3%
Price Change 5Y
-91.8%
1M CAGR (ann.)
8.0%
1Y CAGR (ann.)
-2.2%
5Y CAGR (ann.)
-40.3%
All-Time CAGR
-5.6%

Valuation

PE Ratio
-3.64
Forward PE
70.63
PEG Ratio
-0.10
Forward PEG
0.21
PS Ratio
28.69
Forward PS
14.10
PB Ratio
2.35
P/FCF Ratio
-3.66
P/Adj. FCF Ratio
-2.75
P/OCF Ratio
-3.51
EV/Sales
22.57
EV/EBIT
-4.58
EV/EBITDA
-4.70
EV/FCF
-2.88
Earnings Yield
-27.5%
FCF Yield
-27.3%
Adj. FCF Yield
-36.4%

Financial Health

Net Cash
$364.35M
Total Debt
$73.41M
Cash & Short-Term Investments
$437.76M
Total Assets
$857.16M
Current Ratio
6.65
Quick Ratio
6.65
Debt / Equity Ratio
0.10
Debt / EBITDA
-0.26
Debt / FCF
-0.16
OCF / Debt
-6.32
Interest Coverage
0.00
Altman Z-Score
2.87
Piotroski F-Score
4

Margins & Profitability

Gross Profit Margin
-46.5%
Operating Profit Margin
-522.2%
EBITDA Margin
-656.0%
Net Profit Margin
-672.2%
FCF Margin
-783.3%
Adj. FCF Margin
-1044.5%
SBC / Revenue
261.2%
SBC Impact (per share)
-33.4%

Returns

Return on Assets
-46.7%
Return on Equity
-57.8%
Return on Invested Capital
-52.9%
Return on Capital Employed
-54.5%
Return on Tangible Assets
-46.7%

Historical Growth (CAGR)

Revenue CAGR 3Y
3.9%
Revenue CAGR 5Y
7.3%
Revenue CAGR 10Y
20.3%
EPS CAGR 3Y
23.5%
EPS CAGR 5Y
9.8%
EPS CAGR 10Y
-11.4%
FCF CAGR 3Y
-9.8%
FCF CAGR 5Y
-7.1%
FCF CAGR 10Y
-21.7%

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
39
EPS Growth Next 3Y
44.3%
Revenue Growth Next 3Y
153.1%
Earnings Date
N/A
EPS Estimate (next Q)
N/A
EPS Growth Est (next Q)
N/A
Revenue Est (next Q)
N/A
Revenue Growth Est (next Q)
N/A

Fair Value Estimates

Graham Number
N/A
Graham Upside
N/A
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$23
Price Target Upside
88.2%

Cash Flow

Operating Cash Flow
$-463.99M
Free Cash Flow
$-466.11M
Adj. Free Cash Flow
$-621.54M
FCF Per Share
-$3.49
OCF Per Share
-$3.48
OCF/S Ratio
-779.7%

Income Statement

Revenue
$59.51M
Gross Profit
$-35.32M
Operating Income
$-310.72M
EBITDA
$-285.83M
Net Income
$-399.98M
EPS (Diluted)
-$3.36
Revenue / Employee
$157.84K
Profit / Employee
$-1.06M
Employees
377

© 2026 bestshares.com. All rights reserved.